Kodiak Sciences Presents Promising KSI-301 Durability Data

(RTTNews) - Kodiak Sciences Inc. (KOD), on Sunday, announced emerging durability data in patients with wet age-related macular degeneration treated in its Phase 1b clinical study of its investigational therapy KSI-301.

KSI-301 is an anti-VEGF (vascular endothelial growth factor) antibody biopolymer conjugate, which is under a phase Ib open-label multiple-dose study in patients with anti-VEGF treatment naïve neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion (RVO).

The emerging durability data were from the cohort of treatment-naïve wet AMD patients, and all the patients achieved a treatment-free interval of three months or longer, with the majority reaching a four- or five-month interval and continuing to be followed without retreatment to date.

Further details of the phase 1b study results including durability of KSI-301 in Retinal Vein Occlusion and Diabetic Macular Edema are expected to be presented at the American Academy of Ophthalmology Retina Subspecialty Day on October 11, 2019.

KOD closed at $14.99 on Friday gaining 6.69%.